Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Zymeworks merger values each Theravance share at $17 cash plus one CVR, creating a defined upfront exit value with additional contingent upside.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Zymeworks merger values each Theravance share at $17 cash plus one CVR, creating a defined upfront exit value with additional contingent upside
- CVRs provide pro rata rights to 80% of ampreloxetine license proceeds, $50 million upon qualifying first commercial sale, and 10% of net sales
- Closing targeted for the second half of 2026, subject to two-thirds shareholder approval, HSR clearance, and customary conditions
- Deal termination fees are $32.515 million for either party in specified circumstances, potentially limiting alternative bids
- CVRs are non-transferable, unlisted, and speculative, with payments potentially extending through the later of patent expiration or loss of exclusivity
Item 7.01 · Regulation FD Disclosure
- Regulation FD disclosure furnished under Item 7.01
- Information not deemed “filed” under Exchange Act Section 18
- Disclosure not incorporated by reference into Securities Act or Exchange Act filings absent specific reference
Item 8.01 · Other Events
- Merger Agreement announced June 29, 2026, creating a potentially material strategic and ownership event
- Investors should review Exhibit 99.1 for transaction terms, consideration, closing conditions, and shareholder implications
Item EX-99.1 · Exhibit EX-99.1
- Zymeworks acquisition provides $17.00 cash per share, valuing Theravance Biopharma’s equity at approximately $929 million
- Shareholders receive a CVR for 80% of net proceeds from ampreloxetine monetization over 10 years
- Transaction represents premiums of 22% to March 3, 2026 closing price and 10% to volume-weighted average price since then
- Closing targeted for the second half of 2026, subject to shareholder approval, regulatory approvals, and customary conditions
- Strategic review culminates in sale after TRELEGY royalty monetization for $225 million in 2025 and organizational restructuring
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.